State Street’s aTyr Pharma ATYR Stock Holding History

State Street’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$295K	Sell	494,951 -1,259,448	-72%	-$823K	﹤0.01%	3721
2026 Q1	$1.37M	Buy	1,754,399 +29,556	+2%	+$25K	﹤0.01%	3408
2025 Q4	$1.35M	Sell	1,724,843 -2,471,323	-59%	-$2.03M	﹤0.01%	3457
2025 Q3	$3.03M	Buy	4,196,166 +2,956,503	+238%	+$13.4M	﹤0.01%	3196
2025 Q2	$6.29M	Buy	1,239,663 +872,353	+237%	+$3.43M	﹤0.01%	2837
2025 Q1	$1.11M	Buy	367,310 +66,800	+22%	+$244K	﹤0.01%	3405
2024 Q4	$1.09M	Buy	300,510 +132,202	+79%	+$400K	﹤0.01%	3474
2024 Q3	$296K	Hold	168,308	–	–	﹤0.01%	3721
2024 Q2	$263K	Buy	168,308 +1,500	+0.9%	+$2.61K	﹤0.01%	3741
2024 Q1	$325K	Hold	166,808	–	–	﹤0.01%	3758
2023 Q4	$235K	Hold	166,808	–	–	﹤0.01%	3864
2023 Q3	$264K	Hold	166,808	–	–	﹤0.01%	3855
2023 Q2	$360K	Buy	166,808 +83,900	+101%	+$183K	﹤0.01%	3793
2023 Q1	$174K	Hold	82,908	–	–	﹤0.01%	4124
2022 Q4	$182K	Hold	82,908	–	–	﹤0.01%	4144
2022 Q3	$249K	Hold	82,908	–	–	﹤0.01%	4040
2022 Q2	$235K	Hold	82,908	–	–	﹤0.01%	4126
2022 Q1	$444K	Buy	82,908 +26,909	+48%	+$152K	﹤0.01%	4101
2021 Q4	$418K	Hold	55,999	–	–	﹤0.01%	4087
2021 Q3	$508K	Buy	55,999 +800	+1%	+$4.79K	﹤0.01%	3973
2021 Q2	$269K	Buy	+55,199	New	+$235K	﹤0.01%	4103
2016 Q2	–	Sell	-4,878	Closed	-$270K	–	3769
2016 Q1	$270K	Buy	4,878 +1,664	+52%	+$126K	﹤0.01%	3457
2015 Q4	$444K	Sell	3,214 -7	-0.2%	-$996	﹤0.01%	3355
2015 Q3	$461K	Buy	3,221 +558	+21%	+$127K	﹤0.01%	3351
2015 Q2	$691K	Buy	+2,663	New	+$827K	﹤0.01%	3313

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street's ATYR Position: Q2 2026 in Review

State Street reduced its aTyr Pharma (ATYR) stake by 72% in Q2 2026, selling an estimated $823K and leaving 494,951 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #3721.

State Street first reported a position in ATYR in Q2 2015 and has held it in 25 quarters since. The position peaked at $6.29M in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

State Street held 494,951 shares of aTyr Pharma worth $295K as of Q2 2026.
State Street sold 1,259,448 aTyr Pharma shares in Q2 2026, an estimated $823K.
aTyr Pharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3721 holding.
State Street first reported a position in aTyr Pharma in Q2 2015 and has held it in 25 quarters since.
State Street's aTyr Pharma position peaked at $6.29M in Q2 2025.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.